Review
Nature Reviews Drug Discovery 4, 928-940 (November 2005) | doi:10.1038/nrd1877
Case history: Acyclic nucleoside phosphonates: a key class of antiviral drugs
Erik De Clercq1 & Antonín Holý2 About the authors
Abstract
Almost 20 years after the broad antiviral activity spectrum of the first acyclic nucleoside phosphonates was described, several of these compounds have become important therapies for DNA virus and retrovirus infections. Here, we review the discovery and development of acyclic nucleoside phosphonates, focusing on cidofovir and its potential in the treatment of various herpes-, papilloma-, polyoma-, adeno- and pox-virus infections, adefovir for the treatment of hepatitis B and tenofovir for the treatment of AIDS and the prevention of HIV infections.
- View At a Glance
Author affiliations
-
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
Email: erik.declercq@rega.kuleuven.ac.be -
Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610 Prague, Czech Republic.
Email: holy@uochb.cas.cz
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infectionNature Letters to Editor (09 Feb 2006)
See all 8 matches for Research